全文获取类型
收费全文 | 932588篇 |
免费 | 67911篇 |
国内免费 | 1369篇 |
专业分类
耳鼻咽喉 | 13016篇 |
儿科学 | 24461篇 |
妇产科学 | 23409篇 |
基础医学 | 133140篇 |
口腔科学 | 28367篇 |
临床医学 | 80757篇 |
内科学 | 183118篇 |
皮肤病学 | 19282篇 |
神经病学 | 72189篇 |
特种医学 | 37378篇 |
外国民族医学 | 81篇 |
外科学 | 152490篇 |
综合类 | 18039篇 |
现状与发展 | 1篇 |
一般理论 | 235篇 |
预防医学 | 61680篇 |
眼科学 | 21323篇 |
药学 | 72807篇 |
3篇 | |
中国医学 | 2125篇 |
肿瘤学 | 57967篇 |
出版年
2018年 | 9052篇 |
2017年 | 7111篇 |
2016年 | 7861篇 |
2015年 | 8975篇 |
2014年 | 12150篇 |
2013年 | 17678篇 |
2012年 | 24412篇 |
2011年 | 25316篇 |
2010年 | 14966篇 |
2009年 | 14444篇 |
2008年 | 24877篇 |
2007年 | 26000篇 |
2006年 | 26806篇 |
2005年 | 25729篇 |
2004年 | 24836篇 |
2003年 | 23801篇 |
2002年 | 23370篇 |
2001年 | 54912篇 |
2000年 | 56685篇 |
1999年 | 46933篇 |
1998年 | 10340篇 |
1997年 | 9055篇 |
1996年 | 9176篇 |
1995年 | 8919篇 |
1994年 | 8281篇 |
1993年 | 7602篇 |
1992年 | 35554篇 |
1991年 | 34030篇 |
1990年 | 32823篇 |
1989年 | 31982篇 |
1988年 | 29071篇 |
1987年 | 28344篇 |
1986年 | 26357篇 |
1985年 | 25225篇 |
1984年 | 17878篇 |
1983年 | 15171篇 |
1982年 | 7800篇 |
1981年 | 6763篇 |
1979年 | 15836篇 |
1978年 | 10625篇 |
1977年 | 9068篇 |
1976年 | 7901篇 |
1975年 | 8655篇 |
1974年 | 10516篇 |
1973年 | 9902篇 |
1972年 | 9406篇 |
1971年 | 8881篇 |
1970年 | 8465篇 |
1969年 | 7957篇 |
1968年 | 7222篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
992.
Wyatt T. Clark Laura Kasak Constantina Bakolitsa Zhiqiang Hu Gaia Andreoletti Giulia Babbi Yana Bromberg Rita Casadio Roland Dunbrack Lukas Folkman Colby T. Ford David Jones Panagiotis Katsonis Kunal Kundu Olivier Lichtarge Pier L. Martelli Sean D. Mooney Conor Nodzak Lipika R. Pal Predrag Radivojac Castrense Savojardo Xinghua Shi Yaoqi Zhou Aneeta Uppal Qifang Xu Yizhou Yin Vikas Pejaver Meng Wang Liping Wei John Moult Guoying Karen Yu Steven E. Brenner Jonathan H. LeBowitz 《Human mutation》2019,40(9):1519-1529
The NAGLU challenge of the fourth edition of the Critical Assessment of Genome Interpretation experiment (CAGI4) in 2016, invited participants to predict the impact of variants of unknown significance (VUS) on the enzymatic activity of the lysosomal hydrolase α‐N‐acetylglucosaminidase (NAGLU). Deficiencies in NAGLU activity lead to a rare, monogenic, recessive lysosomal storage disorder, Sanfilippo syndrome type B (MPS type IIIB). This challenge attracted 17 submissions from 10 groups. We observed that top models were able to predict the impact of missense mutations on enzymatic activity with Pearson's correlation coefficients of up to .61. We also observed that top methods were significantly more correlated with each other than they were with observed enzymatic activity values, which we believe speaks to the importance of sequence conservation across the different methods. Improved functional predictions on the VUS will help population‐scale analysis of disease epidemiology and rare variant association analysis. 相似文献
993.
Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
Monica Y. Nio Stijn L.M. in 't Groen Atze J. Bergsma Nadine A.M.E. van der Beek Marian Kroos Marianne Hoogeveen‐Westerveld Ans T. van der Ploeg W.W.M. Pim Pijnappel 《Human mutation》2019,40(11):1954-1967
Pompe disease is an autosomal recessive lysosomal storage disorder caused by disease‐associated variants in the acid alpha‐glucosidase (GAA) gene. The current Pompe mutation database provides a severity rating of GAA variants based on in silico predictions and expression studies. Here, we extended the database with clinical information of reported phenotypes. We added additional in silico predictions for effects on splicing and protein function and for cross reactive immunologic material (CRIM) status, minor allele frequencies, and molecular analyses. We analyzed 867 patients and 562 GAA variants. Based on their combination with a GAA null allele (i.e., complete deficiency of GAA enzyme activity), 49% of the 422 disease‐associated variants could be linked to classic infantile, childhood, or adult phenotypes. Predictions and immunoblot analyses identified 131 CRIM negative and 216 CRIM positive variants. While disease‐associated missense variants were found throughout the GAA protein, they were enriched up to seven‐fold in the catalytic site. Fifteen percent of disease‐associated missense variants were predicted to affect splicing. This should be confirmed using splicing assays. Inclusion of clinical severity rating in the Pompe mutation database provides an invaluable tool for diagnosis, prognosis of disease progression, treatment regimens, and the future development of personalized medicine for Pompe disease. 相似文献
994.
Y. Fukui Y. Okumura K. Uchiya Y. Komori K. Ogawa T. Nikai Y. Hasegawa 《Journal de Mycologie Médicale》2019,29(4):345-351
PurposeElastase, produced by Aspergillus fumigatus and A. flavus, is an important pathogenic factor in pulmonary aspergillosis. We investigated the possibility of using A. fumigatus-derived A. fumigatus elastase inhibitor (AFUEI) as a therapeutic agent. As native-AFUEI (N-AFUEI) has an extremely low yield, we generated a synthetic-AFUEI (S-AFUEI) and investigated whether S-AFUEI has a biological activity against A. fumigatus elastase (AFUE) and inhibits cytotoxicity.MethodologyA. fumigatus was cultured in Yeast Carbon Base (YCB) -elastin culture medium for 3–7 days, and AFUE was purified by chromatography using DE52 cellulose and Sephadex G-75 column. Elastolytic activity was examined using Glt-Ala-Ala-Pro-Leu-pNA (GAAPLNA) as the substrate. The hydrolytic activity of AFUE was determined using the characteristic substrates, fibrinogen and collagen (Type IV), and human cell cytotoxicity was measured colorimetrically. Furthermore, the inhibitory effect of S-AFUEI on these activities was examined.ResultsWe confirmed that S-AFUEI demonstrated elastase inhibitory activity and heat stability equivalent to that demonstrated by N-AFUEI, and inhibited human collagen hydrolytic activity and human fibrinogen hydrolytic activity. Further, S-AFUEI inhibited cytotoxicity in AFUE human pulmonary artery endothelial cells (HPAEC), human small airway epithelial cells (HSAEC), and human pulmonary alveolar epithelial cells (HPAEpiC).ConclusionAs S-AFUEI strongly inhibited cytotoxicity induced by elastase in human-derived cells, it could prove beneficial for the treatment of pulmonary aspergillosis. 相似文献
995.
T. Vermeire C. Barbezange A. Francart A. Hamouda A. Litzroth V. Hutse L. Martens E. Vandermarliere S. Van Gucht 《Clinical microbiology and infection》2019,21(7):907.e1-907.e6
ObjectivesMumps used to affect children between 2 and 15 years old. The mumps–measles–rubella (MMR) vaccine is available, with vaccine coverage rate of about 85% after two vaccine doses. Recently new mumps outbreaks have emerged in highly vaccinated populations; the causes for these new outbreaks are yet unknown. We tested if a difference in seroneutralizing capacity against the vaccine and wild-type viruses existed and if waning immunity could be detected.MethodsIn this study, 570 serum samples (age group 2–3 years (n = 96), 8–9 years (n = 95), 13–14 years (n = 94), 18–20 years (n = 96), 24–26 years (n = 92) and 50 + years (n = 97)) in Belgium were tested in the rapid fluorescent foci inhibition test for their neutralizing capacity against the vaccine and wild-type viruses.ResultsNeutralizing antibodies against the vaccine strain were present in 84% (81/97) of the 2–3-year, 74% (70/95) of the 8–9-year, 81% (76/94) of the 13–14-year, 76% (73/96) of the 18–20-year, 67% (62/92) of the 24–26-year and 77% (75/97) of the 50+-year age group serum samples. For all age groups, only about half of these serum samples were also positive for the wild-type virus. The geometric mean titres for the vaccine and wild-type virus for all younger age groups, except for 24–26 years, were significantly different, demonstrating poor in vitro cross-neutralization.ConclusionsA possible contribution of antigenic differences between the genotype A and G mumps virus as well as other immune factors, in addition to lower-than-optimal vaccination coverage and waning immunity, could explain the poor in vitro cross-neutralization and should be further studied. 相似文献
996.
P. Oakeshott S. Kerry-Barnard C. Fleming R. Phillips V.M. Drennan E.J. Adams W. Majewska E.M. Harding-Esch E.C. Cousins T. Planche A. Green R.I. Bartholomew S.T. Sadiq F. Reid 《Clinical microbiology and infection》2019,21(7):865-871
ObjectivesWe conducted a cluster-randomized feasibility trial of 90-minute Chlamydia trachomatis tests and same day on-site treatment (‘Test n Treat/TnT’) in six technical colleges in London, England, to assess TnT uptake rates; follow-up rates; prevalence of C. trachomatis at baseline and 7 months; time to treatment; acceptability of TnT.MethodsParticipants completed questionnaires and provided genitourinary samples at baseline and 7 months. Participants were informed that baseline samples would not be tested for 7 months and were advised to get screened independently. Colleges were randomly allocated 1:1 to intervention (TnT) or control (no TnT).One month and 4 months post recruitment, participants at intervention colleges were texted invitations for on-site free C. trachomatis tests. A purposive sample of students who did/did not attend for screening were interviewed (n = 26).ResultsFive hundred and nine sexually active students were recruited: median age 17.9 years, 47% male, 50% black ethnicity, 55% reporting two or more sexual partners in the previous year. TnT uptake was 13% (33/259; 95% CI 8.9–17.4%) at 1 month and 10% (26/259; 6.7–14.4%) at 4 months with overall C. trachomatis positivity 5.1% (3/59; 1.1–14.2%). Follow-up at 7 months was 62% (317/509) for questionnaires and 52% (264/509) for samples. C. trachomatis prevalence was 6.2% (31/503) at baseline and 6.1% (16/264) at 7 months. Median time from test to treatment was 15 h. Interviews suggested low test uptake was associated with not feeling at risk, perceptions of stigma, and little knowledge of sexually transmitted infections (STIs).ConclusionsDespite high C. trachomatis rates at baseline and follow-up, uptake of testing was low. Like many countries, England urgently needs better sex education, including making STI testing routine/normal.Trial registration ISRCTN58038795 相似文献
997.
O.C. Durojaiye E.I. Kritsotakis P. Johnston T. Kenny F. Ntziora K. Cartwright 《Clinical microbiology and infection》2019,21(7):905.e1-905.e7
ObjectivesOutpatient parenteral antimicrobial therapy (OPAT) is increasingly used to treat a wide range of infections. However, there is risk of hospital readmissions. The study aim was to develop a prediction model for the risk of 30-day unplanned hospitalization in patients receiving OPAT.MethodsUsing a retrospective cohort design, we retrieved data on 1073 patients who received OPAT over 2 years (January 2015 to January 2017) at a large teaching hospital in Sheffield, UK. We developed a multivariable logistic regression model for 30-day unplanned hospitalization, assessed its discrimination and calibration abilities, and internally them validated using bootstrap resampling.ResultsThe 30-day unplanned hospitalization rate was 11% (123/1073). The main indication for hospitalization was worsening or nonresponse of infection (52/123, 42%). The final regression model consisted of age (adjusted odds ratio (aOR), 1.18 per decade; 95% confidence interval (CI), 1.04–1.34), Charlson comorbidity score (aOR, 1.11 per unit increase; 95% CI, 1.00–1.23), prior hospitalizations in past 12 months (aOR, 1.30 per admission; 95% CI, 1.17–1.45), concurrent intravenous antimicrobial therapy (aOR, 1.89; 95% CI, 1.03–3.47) and endovascular infection (aOR, 3.51; 95% CI, 1.49–8.28). Mode of OPAT treatment was retained in the model as a confounder. The model had adequate concordance (c-statistic 0.72; 95% CI 0.67–0.77) and calibration (Hosmer-Lemeshow p 0.546; calibration slope 0.99; 95% CI 0.78–1.21), and low degree of optimism (bootstrap optimism corrected c-statistic, 0.70).ConclusionsWe identified a set of six important predictors of unplanned hospitalization based on readily available data. The prediction model may help improve OPAT outcomes through better identification of high-risk patients and provision of tailored care. 相似文献
998.
A. Antonelli M. Coppi G. Camarlinghi E.M. Parisio M. Nardone E. Riccobono T. Giani R. Mattei G.M. Rossolini 《Clinical microbiology and infection》2019,21(11):1432.e1-1432.e4
ObjectivesThe aim was to evaluate different methods for testing carbapenem susceptibility of Escherichia coli producing KPC-type carbapenemase.MethodsSusceptibility to imipenem, meropenem and ertapenem was assayed using the reference broth microdilution method and several commercial methods (Vitek2, MicroScan, Etest, MIC Test Strip) starting from the same bacterial suspension. Susceptibility to imipenem and meropenem was also tested by Sensititre and disc diffusion (Bio-Rad). Results were interpreted according to EUCAST clinical breakpoints. Essential agreement (EA), category agreement (CA) and error rates were calculated as described by the International Organization for Standardization (ISO) guidelines and also considering the new EUCAST definitions. Genotypic diversity of isolates was evaluated with a RAPD profiling protocol.ResultsOf 54 KPC-positive E. coli isolates, 5.6%, 7.4% and 0% were susceptible standard dosing regimen (S), 55.6%, 72.2% and 0% susceptible increased exposure (I), and 38.9%, 20.4% and 100.0% resistant (R) to imipenem, meropenem and ertapenem, respectively, using the reference broth microdilution method. CA lower than 90% were observed with all systems for imipenem and meropenem using both the ISO and the modified EUCAST criteria. With ertapenem, CA >90% was observed with all methods except Vitek2. RAPD profiling revealed a remarkable genotypic diversity of the isolates, supporting that results were not biased by an oligoclonal nature of the collection.ConclusionsCommercial methods can be unreliable for testing susceptibility to carbapenems of KPC-producing E. coli. Susceptibility should be confirmed by reference broth microdilution. 相似文献
999.
1000.
BackgroundMicrobial whole genome sequencing (WGS) has many advantages over standard microbiological methods. However, it is not yet widely implemented in routine hospital diagnostics due to notable challenges.ObjectivesThe aim was to extract managerial, financial and clinical criteria supporting the decision to implement WGS in routine diagnostic microbiology, across different operational models of implementation in the hospital setting.MethodsThis was a systematic review of literature identified through PubMed and Web of Science. English literature studies discussing the applications of microbial WGS without limitation on publication date were eligible. A narrative approach for categorization and synthesis of the sources identified was adopted.ResultsA total of 98 sources were included. Four main alternative operational models for incorporating WGS in clinical microbiology laboratories were identified: full in-house sequencing and analysis, full outsourcing of sequencing and analysis and two hybrid models combining in-house/outsourcing of the sequencing and analysis components. Six main criteria (and multiple related sub-criteria) for WGS implementation emerged from our review and included cost (e.g. the availability of resources for capital and operational investment); manpower (e.g. the ability to provide training programmes or recruit trained personnel), laboratory infrastructure (e.g. the availability of supplies and consumables or sequencing platforms), bioinformatics requirements (e.g. the availability of valid analysis tools); computational infrastructure (e.g. the availability of storage space or data safety arrangements); and quality control (e.g. the existence of standardized procedures).ConclusionsThe decision to incorporate WGS in routine diagnostics involves multiple, sometimes competing, criteria and sub-criteria. Mapping these criteria systematically is an essential stage in developing policies for adoption of this technology, e.g. using a multicriteria decision tool. Future research that will prioritize criteria and sub-criteria that were identified in our review in the context of operational models will inform decision-making at clinical and managerial levels with respect to effective implementation of WGS for routine use. Beyond WGS, similar decision-making challenges are expected with respect to future integration of clinical metagenomics. 相似文献